
Keywords: AUC; SGLT2 inhibitor; DPP4 inhibitor; Canagliflozin; Combination treatment; Glucagon-like peptide-1; aGLP-1; active GLP-1; ANOVA; Analysis of variance; AUC; Area under the curve; CMA; (2S)-2-Cyano-1-[trans-4-(morpholinocarbonyl)cyclohexylamino]acetylpyrrolidin